PURPOSE OF REVIEW: High-risk human papillomaviruses (HPVs) are implicated in the development of a subset of head and neck squamous cell cancers (HNSCCs), especially those arising from the lingual or palatine tonsils. HPV-associated HNSCCs represent a different disease entity from those associated with the traditional risk factors of tobacco and alcohol use. The demonstration that HPV is causally associated with a subset of HNSCC has tremendous clinical and research implications. RECENT FINDINGS: In recent years, there has been an increase in the annual incidence of HPV-related HNSCC in the United States and Europe. It has now become clear that a subset of HNSCC is a sexually transmitted disease with distinct pathogenesis and clinical/pathological features. HPV-associated HNSCCs have a better prognosis compared with stage-matched non-HPV-related HNSCC in the majority of studies. Research efforts are now focusing on deintensification of treatment to reduce treatment-associated morbidity. HPV-targeted therapies are under investigation. SUMMARY: The increasing incidence of HPV-related HNSCC has led to the development of novel research strategies in HNSCC. This review summarizes the epidemiology, clinical presentation, molecular pathogenesis, diagnosis, and therapy of HPV-associated HNSCC; it also summarizes how a better understanding of the molecular pathogenesis of HPV-associated HNSCC is expected to change treatment.
PURPOSE OF REVIEW: High-risk human papillomaviruses (HPVs) are implicated in the development of a subset of head and neck squamous cell cancers (HNSCCs), especially those arising from the lingual or palatine tonsils. HPV-associated HNSCCs represent a different disease entity from those associated with the traditional risk factors of tobacco and alcohol use. The demonstration that HPV is causally associated with a subset of HNSCC has tremendous clinical and research implications. RECENT FINDINGS: In recent years, there has been an increase in the annual incidence of HPV-related HNSCC in the United States and Europe. It has now become clear that a subset of HNSCC is a sexually transmitted disease with distinct pathogenesis and clinical/pathological features. HPV-associated HNSCCs have a better prognosis compared with stage-matched non-HPV-related HNSCC in the majority of studies. Research efforts are now focusing on deintensification of treatment to reduce treatment-associated morbidity. HPV-targeted therapies are under investigation. SUMMARY: The increasing incidence of HPV-related HNSCC has led to the development of novel research strategies in HNSCC. This review summarizes the epidemiology, clinical presentation, molecular pathogenesis, diagnosis, and therapy of HPV-associated HNSCC; it also summarizes how a better understanding of the molecular pathogenesis of HPV-associated HNSCC is expected to change treatment.
Authors: L Mannarini; V Kratochvil; L Calabrese; L Gomes Silva; P Morbini; J Betka; M Benazzo Journal: Acta Otorhinolaryngol Ital Date: 2009-06 Impact factor: 2.124
Authors: Brandon C Leonard; Eliot D Lee; Neil E Bhola; Hua Li; Kristian K Sogaard; Christopher J Bakkenist; Jennifer R Grandis; Daniel E Johnson Journal: Oral Oncol Date: 2019-06-06 Impact factor: 5.337
Authors: M Vatca; J T Lucas; J Laudadio; R B D'Agostino; J D Waltonen; C A Sullivan; R Rouchard-Plasser; M Matsangou; J D Browne; K M Greven; M Porosnicu Journal: Oral Oncol Date: 2014-07-03 Impact factor: 5.337
Authors: Darío García-Carracedo; Yi Cai; Wanglong Qiu; Kiyoshi Saeki; Richard A Friedman; Andrew Lee; Yinglu Li; Elizabeth M Goldberg; Elias E Stratikopoulos; Ramon Parsons; Chao Lu; Argiris Efstratiadis; Elizabeth M Philipone; Angela J Yoon; Gloria H Su Journal: Mol Cancer Res Date: 2020-03-09 Impact factor: 5.852